Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors1

Translational Oncology

Volumn 4, Issue 3, 2011, Pages 147-156

  Stearns, Mark E ^a   Wang, Min ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOCETAXEL; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; PACLITAXEL; PROTEIN P21; PROTEIN P53; PROTEIN P73; TAXANE DERIVATIVE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROSTATE CANCER; TUMOR GROWTH;

EID: 79957898286     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10286     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, and Wingo PA (2000). Cancer statistics, 2000. CA Cancer J Clin 50, 7-33.
2. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, et al. (2000). Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 18, 3240-3246.
3. Oh WK and Kantoff PW (1999). Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 17, 3664-3675.
4. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bafiella E, et al. (2000). Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163, 834-837.
5. Petrylak DP (2000). Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 27, 24-29.
6. Stearns ME, Amatangelo MD, Varma D, Sell C, and Goodyear SM (2010). Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies. Inhibition of metastatic tumor growth in SCID mice. Am J Pathol 177, 3169-3179.
7. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, et al. (2009). Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 10, 3808-3814.
8. Fu H, He J, Mei F, Zhang Q, Hara Y, Ryota S, Lubet RA, Chen R, Chen DR, and You M (2009). Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev Res (Phila) 2, 531-537.
9. Stearns ME and Wang M (1991). Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in s.c.i.d. mice. Differentiation 48, 115-125.
10. Denizot F and Lang R (1986). Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89, 271-277.
11. Stearns ME, Jason B, Zhang H, Francis MK, and Sell C (2005). Insulin-like growth factor 1 (IGF-1) induction of vascular endothelial growth factor (VEGF) is dependent upon activated Ras. Cancer Res 65, 2085-2088.
12. Sambrook J and Russell DW (2003). In Molecular Cloning: A Laboratory Manual Molecular Biology; Biochemistry Laboratory Manuals (3rd ed). Cold Spring Harbor Press, Cold Spring Harbor, NY. Vol. 1. pp. 2.82-2.108.
13. Chahinian AP, Mandell JP, Gluck H, Naim H, Teirstein AS, and Holland JF (1998). Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 67, 104-111.
14. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, and Potier P (1986). Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 17, 137-142.
15. Steel GG and Peckham MJ (1993). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5, 85-91.
16. Aoe K, Kiura K, Ueoka H, Tabata M,Matsumura T, Chikamor IM,Matsushita A, Kohara H, and Harada M (1999). Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19, 291-299.
17. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, et al. (1996). Clinical development plan: tea extracts. Green tea polyphenols, epigallocatechin gallate. J Cell Biochem Suppl 26, 236-257.
18. Bushman JL (1998). Green tea and cancer in humans: a review of the literature. Nutr Cancer 31, 151-159.
19. Mukhtar T, Wang Z, Katiyer SK, and Agarwal R (1992). Tea components: antimutagenic and anticarcinogenic effects. Prev Med 21, 351-360.
20. Katiyer SK, Agarwal R, and Mukhtar H (1994). Inhibition of spontaneous and photo-enhanced lipid peroxidation in mouse epidermal microsomes by epicatechin derivatives from green tea. Cancer Lett 79, 61-66.
21. Nishida H, Omori M, Fukutomi Y, Ninomiya M, Nishiwaki S, Suganuma M, Moriwaki H, and Muto Y (1994). Inhibitory effects of (-)-epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatomaderived PLC/PRF/5 cells. Jpn J Cancer Res 85, 221-225.
22. Sagesaka Y, Sugiura T, Miwa Y, Yamaguchi K, and Kyuki K (1996). Effect of tea-leaf saponin on blood pressure of spontaneously hypertensive rats. Yakugaku Zasshi 116, 388-395.
23. Sano M, Takahashi Y, Yoshino K, Shimoi K, Nakamura Y, Tomita I, Oguni I, and Konomoto H (1995). Effect of tea (Camellia sinensis L.) on lipid peroxidation in rat liver and kidney: a comparison of green and black tea feeding. Biol Pharm Bull 18, 1006-1008.
24. Nagata T (1986). Studies on useful components of tea in leaves of the genus Camellia. Bull Natl Res Inst Tea 21, 60-120.
25. Sadzuka Y, Sugiyama T, and Sonobe T (2000). Efficacies of tea components on Dox induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 114, 155-162.
26. Sadzuka Y, Sugiyama T, and Hirota S (1998). Modulation of cancer chemotherapy by green tea. Clin Cancer Res 4, 153-156.
27. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, and Niedzwiecki A (2010). Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24, 747-757.
28. Farabegoli F, Papi A, and Orlandi M (2011). (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep 31, 99-108.
29. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, and Fujiki H (1999). Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59, 44-47.
30. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith- Sorensen B, Montesano R, and Harris CC (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22, 3551-3555.
31. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, and Stark GR (1998). The p53 network. J Biol Chem 273, 14-23.
32. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
33. Miyashita T and Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax. Cell 80, 293-299.
34. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, and Bradley A (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221.
35. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, and Melino G (2000). The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113, 1661-1670.
36. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.
37. Zhu J, Jiang J, Zhou W, and Chen X (1998). The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58, 5061-5065.